Navigation Links
Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Date:11/7/2012

didate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which has completed Phase 1/2 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "could," "potential," "may" and similar references to future periods.  Examples of forward-looking statements include our current views as to the potential of etirinotecan pegol as a potential new therapy for patients with metastatic breast cancer; the expected enrollment completion date for the BEACON trial; the value of our polymer conjugate technology platform; and the potential of
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
3. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
7. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
10. Life Technologies Announces Next-Gen Digital PCR Instrument Designed for Widespread Adoption
11. Blue Belt Technologies Announces First United Kingdom-Based NavioPFS Unicondylar Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  eRelevance Corporation ( www.erelevancecorp.com ), ... that it has completed integration with Nextech, a ... Surgery and Dermatology practices. "Integration allows ... healthcare practices using Nextech," stated Bob Fabbio ... information from the EMR we are able to ...
(Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
(Date:8/21/2014)...  Zacks.com announces the list of stocks featured in the ... the latest news and events impacting stocks and the financial ... HPQ - Free Report ), IBM (NYSE: IBM ... - Free Report ), GlaxoSmithKline plc (NYSE: GSK - ... - Free Report ). Today, Zacks is promoting ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11
... Inc., a privately-held developer and marketer of the VerifyNow ... for measuring platelet reactivity to multiple antiplatelet agents, announced ... Portola Pharmaceuticals, Inc. to develop and supply the VerifyNow ... The VerifyNow System is widely used by practicing ...
... SUNNYVALE, Calif., March 2, 2011 Pharmacyclics, Inc. (Nasdaq: ... of PCI-45292, a Btk inhibitor with exceptionally potent anti-arthritis ... results from the current set of preclinical toxicology studies. ... candidate identified within approximately 6 months. ...
Cached Medicine Technology:Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc. 2Update on Preclinical Finding and Development Timeline for PCI-45292 2Update on Preclinical Finding and Development Timeline for PCI-45292 3
(Date:8/21/2014)... 21, 2014 Living in a quality ... that comes along with it. A quality Home Owners ... such amenities are available. , Simpson ... Georgia and Community Association Management, LLC made a recent ... Company to provide an additional amenity for their neighborhood. ...
(Date:8/21/2014)... arteries of chronic kidney disease patients may be a ... new study in the Journal of the American ... the Johns Hopkins Bloomberg School of Public Health assert ... of subclinical atherosclerosis in predicting the risk of heart ... percent of all patients with chronic kidney disease (CKD) ...
(Date:8/21/2014)... Dallas, TX (PRWEB) August 21, 2014 ... August 20 entertained residents with dementia at Silverado Turtle ... Improv Troupe, which consists of entertainers ranging from ages ... each time they perform their 40-minute set. The troupe's ... makes it universal and allows them to touch audiences ...
(Date:8/21/2014)... August 21, 2014 The City of ... for entertainment and programming for its inaugural “Re:Imagine Garden ... October 12, 2014, from 11 a.m. to 4 p.m., ... all cars and the downtown will be filled with ... by Community Arts Resources (CARS), for all to enjoy. ...
(Date:8/21/2014)... Among seniors, dimming vision may be tied to poorer survival, ... people, aged 65 to 84, who were assessed when they ... years later. Vision loss over time was associated with ... study period, the researchers reported. Although the study couldn,t ... Purdue University in West Lafayette, Ind., offered up some theories ...
Breaking Medicine News(10 mins):Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 2Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 3Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2
... new study by Ohio State University researchers has shown ... are not being managed appropriately.,The researchers who looked at ... patients' own descriptions of anxiety after a heart attack ... doctors do not match. In the group of,participants it ...
... been found for detecting upper urinary tract transitional cell ... Canada. This method checks for fibrinogen/fibrin degradation products. It ... to standard urinary cytology. The Researchers compared the efficacy ... cytology in establishing the diagnosis// of transitional cell carcinoma ...
... came up in 1971 argued that people react to ... eventually return to a stable level of well-being. Researchers ... France and England confirmed this theory based on a ... on life satisfaction. 24,000 individuals were followed for 15 ...
... first of its kind study compared a group of whiplash patients ... who suffered a whiplash injury had pain in the neck, head, ... a year. In the study of the two groups, pain in ... a month while in the whiplash injury group patients were still ...
... Examination Survey has now uncovered a link between Periodontal ... of gum disease that causes infection and inflammation of ... of the study where divided into two groups, depending ... an indicator of the presence of periodontal disease. They ...
... Live cancer is one of the most aggressive cancers worldwide ... countries due to hepatitis infection and aflatoxin contamination of foodstuffs. ... Researchers in the US and China have been studying gene ... and found a way of detecting tumors that spread. They ...
Cached Medicine News:
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 7.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 9 mm....
Medicine Products: